Zou Yu-Hui, Cao Yi-Qun, Wang Lai-Xing, Zhang Yu-Hui, Yue Zhi-Jian, Liu Jian-Min
Department of Neurosurgery, Changhai Hospital, Shanghai 200433, P.R. China.
Exp Ther Med. 2011 Jul;2(4):725-729. doi: 10.3892/etm.2011.257. Epub 2011 Apr 19.
Although previous studies have shown that γ-secretase inhibitors significantly suppress tumor growth via anti-angiogenesis, the mechanism involved in the regulation of tumor angiogenesis by γ-secretase inhibitors has not been clearly understood. The objective of this study was to investigate the regulation of vascular endothelial growth factor receptor (VEGFR) and endothelial nitric oxide synthase (eNOS) by a γ-secretase inhibitor in the H5V mouse microvascular endothelial cell line. H5V cells were cultured with different concentrations of the γ-secretase inhibitor DAPT for 48 h and with 100 μmol/l DAPT at different incubation times. Protein and mRNA expression of VEGFR-1, VEGFR-2, VEGFR-3 and eNOS was measured by Western blotting and real-time PCR, respectively. The VEGFR-2 kinase inhibitor was used to assess the role of VEGFR-2 in eNOS regulation. We found that the γ-secretase inhibitor DAPT increased protein and mRNA expression of VEGFR-2 and eNOS, but decreased VEGFR-1 expression and had no significant effect on VEGFR-3. Up-regulation of eNOS was blocked by the VEGFR-2 kinase inhibitor. In conclusion, the γ-secretase inhibitor enhances VEGFR-2 and eNOS expression, and the up-regulation of eNOS is dependent on an increase in VEGFR-2. Thus, we suggest that administration of the γ-secretase inhibitor be combined with disruption of eNOS or interruption of VEGF signaling, which may improve the anti-angiogenic efficacy in tumor treatments.
尽管先前的研究表明,γ-分泌酶抑制剂可通过抗血管生成作用显著抑制肿瘤生长,但γ-分泌酶抑制剂调控肿瘤血管生成的机制尚未完全明确。本研究的目的是探讨γ-分泌酶抑制剂对H5V小鼠微血管内皮细胞系中血管内皮生长因子受体(VEGFR)和内皮型一氧化氮合酶(eNOS)的调控作用。将H5V细胞用不同浓度的γ-分泌酶抑制剂DAPT培养48小时,以及用100μmol/l DAPT在不同孵育时间进行培养。分别通过蛋白质印迹法和实时荧光定量PCR检测VEGFR-1、VEGFR-2、VEGFR-3和eNOS的蛋白及mRNA表达。使用VEGFR-2激酶抑制剂评估VEGFR-2在eNOS调控中的作用。我们发现,γ-分泌酶抑制剂DAPT可增加VEGFR-2和eNOS的蛋白及mRNA表达,但降低VEGFR-1的表达,对VEGFR-3无显著影响。VEGFR-2激酶抑制剂可阻断eNOS的上调。综上所述,γ-分泌酶抑制剂可增强VEGFR-2和eNOS的表达,且eNOS的上调依赖于VEGFR-2的增加。因此,我们建议γ-分泌酶抑制剂的给药可与eNOS的破坏或VEGF信号传导的中断相结合,这可能会提高肿瘤治疗中的抗血管生成疗效。